pyrazines has been researched along with ascorbic acid in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 3 (12.00) | 18.2507 |
| 2000's | 12 (48.00) | 29.6817 |
| 2010's | 8 (32.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gotoh, N; Niki, E | 1 |
| abdel Gayoum, A; Ali, BH; el Gawarsha, K; Fakhri, M | 1 |
| Bentley, PJ; McGahan, MC | 1 |
| Anggard, E; Hink, U; Münzel, T; Skatchkov, MP; Sperling, D | 1 |
| Hiramoto, K; Kato, T; Kikugawa, K; Yanagawa, H | 1 |
| Hiramoto, K; Kato, T; Kikugawa, K | 1 |
| Wang, J; Xing, D | 1 |
| Anderson, KC; Catley, L | 1 |
| He, M; Khuri, FR; Lin, N; Lonial, S; Sun, SY; Wang, B; Yue, P; Zhou, Z; Zou, W | 1 |
| Berenson, JR; Mapes, R; Matous, J; Morrison, B; Swift, RA; Yeh, HS | 1 |
| Baritaki, S; Berenson, JR; Bonavida, B; Campbell, RA; Chen, H; Gordon, M; Pang, S; Said, J; Sanchez, E; Shalitin, D; Steinberg, JA; Wang, C | 1 |
| Bernhardt, PV; Kalinowski, DS; Richardson, DR; Sharpe, PC | 1 |
| Dolcet, X; Encinas, M; Eritja, N; Llobet, D; Llombart-Cussac, A; Marti, RM; Matias-Guiu, X; Schoenenberger, JA; Sorolla, A; Yeramian, A | 1 |
| Abaya, CD; Berenson, JR; Cartmell, A; Duvivier, H; Eades, B; Flam, MS; Hilger, J; Nassir, Y; Patel, R; Swift, RA; Woytowitz, D; Yellin, O | 1 |
| Anderson, KC; Baccarani, M; Calabrese, E; Cavo, M; Chauhan, D; Cirstea, D; Gorgun, G; Hideshima, T; Ikeda, H; Okawa, Y; Perrone, G; Raje, N; Santo, L | 1 |
| Harvey, RD; Lonial, S; Nettles, J; Sun, SY; Wang, B | 1 |
| Bannerman, B; Berger, A; Bolen, J; Claiborne, C; Dick, L; Fleming, P; Hales, P; Jones, M; Kupperman, E; Manfredi, M; Monbaliu, J; Tsu, C; Xu, L; Yu, J | 1 |
| Abe, M; Amou, H; Fujii, S; Harada, T; Hiasa, M; Kagawa, K; Matsumoto, T; Miki, H; Nakamura, S; Nakano, A; Oda, A; Ozaki, S; Takeuchi, K; Watanabe, T | 1 |
| Bashir, Q; Bassett, RL; Champlin, RE; Giralt, SA; Hosing, CM; Khan, H; Orlowski, RZ; Parmar, S; Popat, UR; Qazilbash, MH; Shah, JJ; Shah, N; Sharma, M; Thall, PF; Wang, M | 1 |
| Chavez, M; Cohen, JI; Espey, MG; Levine, M; Shatzer, AN; Tu, H | 1 |
| Chao, NJ; de Castro, CM; Diehl, LF; Gasparetto, C; Gockerman, JP; Held, LA; Horwitz, ME; Long, GD; Moore, JO; Rizzieri, D | 1 |
| Yang, YN; Yu, AN; Zhou, YY | 1 |
| Elliott, JAW; Hahn, J; Jomha, NM; Korbutt, GS; Laouar, L | 1 |
| Dong, R; Elliott, JAW; Jomha, NM; Laouar, L; Wu, K | 1 |
| An, H; An, X; Chen, Y; Dai, X; Guan, S; Huang, B; Huang, Q; Liang, L; Lu, M; Lu, X; Nie, H; Wang, H; Wang, J; Wang, Z; Zhang, H | 1 |
4 trial(s) available for pyrazines and ascorbic acid
| Article | Year |
|---|---|
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Disease-Free Survival; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence; Survival Analysis; Treatment Failure; Treatment Outcome | 2007 |
Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Ascorbic Acid; Boronic Acids; Bortezomib; Humans; Melphalan; Middle Aged; Multiple Myeloma; Pyrazines; Survival Analysis; Treatment Outcome | 2009 |
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Blood Transfusion, Autologous; Boronic Acids; Bortezomib; Disease-Free Survival; Drug Administration Schedule; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Oxides; Prognosis; Pyrazines; Transplantation Conditioning | 2012 |
A Phase I study of arsenic trioxide (Trisenox), ascorbic acid, and bortezomib (Velcade) combination therapy in patients with relapsed/refractory multiple myeloma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Female; Humans; Male; Middle Aged; Multiple Myeloma; Oxides; Pyrazines; Recurrence | 2013 |
21 other study(ies) available for pyrazines and ascorbic acid
| Article | Year |
|---|---|
Rates of interactions of superoxide with vitamin E, vitamin C and related compounds as measured by chemiluminescence.
Topics: Ascorbic Acid; Binding, Competitive; Chromans; Hydrogen-Ion Concentration; Hypoxanthine; Hypoxanthines; Kinetics; Liposomes; Luminescent Measurements; Phosphatidylcholines; Pyrazines; Superoxides; Vitamin E; Xanthine Oxidase | 1992 |
Lipid peroxidation, glutathione and ascorbic acid concentrations in tissues of mice treated with oltipraz: influence of cysteine and olive oil pretreatments.
Topics: Animals; Ascorbic Acid; Brain Chemistry; Cysteine; Glutathione; Kidney; Lipid Peroxidation; Liver; Male; Mice; Olive Oil; Plant Oils; Pyrazines; Thiones; Thiophenes | 1991 |
Stimulation of transepithelial sodium and chloride transport by ascorbic acid. Induction of Na+ channels is inhibited by amiloride.
Topics: Amiloride; Animals; Ascorbic Acid; Biological Transport, Active; Bufo marinus; Chlorides; Cornea; Epithelium; Ion Channels; Kinetics; Pyrazines; Sodium | 1982 |
Quantification of superoxide radical formation in intact vascular tissue using a Cypridina luciferin analog as an alternative to lucigenin.
Topics: Acridines; Animals; Aorta; Ascorbic Acid; Cell Extracts; Electron Spin Resonance Spectroscopy; Luminescent Measurements; Muscle, Smooth, Vascular; omega-N-Methylarginine; Pyrazines; Rabbits; Superoxide Dismutase; Superoxides | 1998 |
Effect of food reductones on the generation of the pyrazine cation radical and on the formation of the mutagens in the reaction of glucose, glycine and creatinine.
Topics: Animals; Antioxidants; Ascorbic Acid; Cations; Creatinine; Electron Spin Resonance Spectroscopy; Food Analysis; Food Contamination; Free Radicals; Glucose; Glycine; In Vitro Techniques; Maillard Reaction; Microsomes, Liver; Mutagenicity Tests; Mutagens; Pyrazines; Rats; Salmonella typhimurium | 2000 |
Prevention of the formation of mutagenic and/or carcinogenic heterocyclic amines by food factors.
Topics: Amines; Animals; Anticarcinogenic Agents; Antimutagenic Agents; Antioxidants; Ascorbic Acid; Cattle; Food; Free Radical Scavengers; Free Radicals; Glucose; Heterocyclic Compounds; Hot Temperature; Imidazoles; Meat; Mutagens; Pyrazines; Quinoxalines | 2000 |
Detection of vitamin C-induced singlet oxygen formation in oxidized LDL using MCLA as a chemiluminescence probe.
Topics: Ascorbic Acid; Imidazoles; Lipoproteins, LDL; Luminescent Measurements; Oxygen; Pyrazines | 2002 |
Velcade and vitamin C: too much of a good thing?
Topics: Antineoplastic Agents; Ascorbic Acid; Boronic Acids; Bortezomib; Humans; Pyrazines; Vitamins | 2006 |
Vitamin C inactivates the proteasome inhibitor PS-341 in human cancer cells.
Topics: Antineoplastic Agents; Antioxidants; Apoptosis; Ascorbic Acid; Blotting, Western; Boronic Acids; Bortezomib; Cell Cycle; Cell Line, Tumor; Drug Interactions; Humans; Proteasome Endopeptidase Complex; Pyrazines | 2006 |
Antimyeloma effects of arsenic trioxide are enhanced by melphalan, bortezomib and ascorbic acid.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Arsenic Trioxide; Arsenicals; Ascorbic Acid; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Enzyme-Linked Immunosorbent Assay; Humans; Immunoglobulin G; Melphalan; Mice; Mice, SCID; Multiple Myeloma; Oxides; Pyrazines; Xenograft Model Antitumor Assays | 2007 |
Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.
Topics: Antineoplastic Agents; Ascorbic Acid; Benzoates; Cell Line, Tumor; Cell Proliferation; Crystallography, X-Ray; Humans; Hydrazones; Hydroxylation; Iron; Iron Chelating Agents; Iron Overload; Iron Radioisotopes; Isonicotinic Acids; Ketones; Ligands; Oxidation-Reduction; Pyrazines; Structure-Activity Relationship | 2008 |
Antioxidants block proteasome inhibitor function in endometrial carcinoma cells.
Topics: Antioxidants; Antipyrine; Apoptosis; Ascorbic Acid; Blotting, Western; Boronic Acids; Bortezomib; Butylated Hydroxyanisole; Caspase 3; Caspase 9; Caspase Inhibitors; Cell Line, Tumor; Cell Survival; Coumarins; Cysteine Proteinase Inhibitors; Dose-Response Relationship, Drug; Edaravone; Endometrial Neoplasms; Ergothioneine; Female; Humans; Leupeptins; Oligopeptides; Proteasome Inhibitors; Pyrazines; Ubiquitin; Vitamin E; Vitamins | 2008 |
Ascorbic acid inhibits antitumor activity of bortezomib in vivo.
Topics: Animals; Antineoplastic Agents; Antioxidants; Ascorbic Acid; Boronic Acids; Bortezomib; Cell Line, Tumor; Cell Proliferation; Humans; Mice; Multiple Myeloma; Proteasome Inhibitors; Pyrazines | 2009 |
Commentary on Perrone et al.: 'vitamin C: not for breakfast anymore...if you have myeloma'.
Topics: Antineoplastic Agents; Antioxidants; Ascorbic Acid; Boronic Acids; Bortezomib; Drug Interactions; Humans; Multiple Myeloma; Pyrazines | 2009 |
Preclinical evaluation of the antitumor activity of bortezomib in combination with vitamin C or with epigallocatechin gallate, a component of green tea.
Topics: Animals; Antineoplastic Agents; Ascorbic Acid; Boronic Acids; Bortezomib; Catechin; Chromatography, Liquid; Drug Screening Assays, Antitumor; Female; Humans; Male; Mice; Mice, SCID; Prostatic Neoplasms; Pyrazines; Tandem Mass Spectrometry; Tea; Xenograft Model Antitumor Assays | 2011 |
Delayed treatment with vitamin C and N-acetyl-L-cysteine protects Schwann cells without compromising the anti-myeloma activity of bortezomib.
Topics: Acetylcysteine; Animals; Antineoplastic Agents; Antioxidants; Ascorbic Acid; Autophagy; Boronic Acids; Bortezomib; Cell Line; Endoplasmic Reticulum; Free Radical Scavengers; Multiple Myeloma; Neuroprotective Agents; Peripheral Nervous System Diseases; Pyrazines; Rats; Schwann Cells | 2011 |
Ascorbic acid kills Epstein-Barr virus positive Burkitt lymphoma cells and Epstein-Barr virus transformed B-cells in vitro, but not in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; Ascorbic Acid; Boronic Acids; Bortezomib; Burkitt Lymphoma; Cell Line, Transformed; Cell Line, Tumor; Cell Survival; Cell Transformation, Viral; Female; Herpesvirus 4, Human; Humans; Mice; Pyrazines; Reactive Oxygen Species; Virus Replication | 2013 |
Kinetics of browning and correlations between browning degree and pyrazine compounds in l-ascorbic acid/acidic amino acid model systems.
Topics: Amino Acids; Ascorbic Acid; Aspartic Acid; Glutamic Acid; Kinetics; Maillard Reaction; Models, Biological; Pyrazines | 2017 |
The effect of additive compounds on glycerol-induced damage to human chondrocytes.
Topics: Aged; Aged, 80 and over; Ascorbic Acid; Cartilage, Articular; Cell Survival; Chondrocytes; Chondroitin Sulfates; Cryopreservation; Cryoprotective Agents; Glucosamine; Glycerol; Humans; Middle Aged; Pyrazines; Vitrification | 2017 |
Evaluation of five additives to mitigate toxicity of cryoprotective agents on porcine chondrocytes.
Topics: Animals; Ascorbic Acid; Cartilage, Articular; Cell Physiological Phenomena; Cell Survival; Chondrocytes; Chondroitin Sulfates; Cryopreservation; Cryoprotective Agents; Glucosamine; Pyrazines; Swine; Tissue Banks; Vitrification | 2019 |
Transcriptome and lipidome profile of human mesenchymal stem cells with reduced senescence and increased trilineage differentiation ability upon drug treatment.
Topics: Ascorbic Acid; Cell Differentiation; Cellular Senescence; Humans; Hypoglycemic Agents; Lipidomics; Mesenchymal Stem Cells; Metformin; Pyrazines; Reverse Transcriptase Inhibitors; Sirolimus; Thiones; Thiophenes; Transcriptome | 2021 |